Skip to content
DraconiticResearch
Search Sources API
201,818 studies31 sourcesUpdated 35 min ago
Peer-reviewedCC BYInternational journal of molecular sciences

FGFR3 Gene Alterations and Protein Expression in Paired TURBT and Radical Cystectomy Archival Specimens of Muscle-Invasive Bladder Cancer.

  • Makito Miyake1
  • Nobutaka Nishimura1
  • Sayuri Ohnishi1
  • Yuki Oda1
  • Takuto Shimizu1
  • Takuya Owari1
  • Kota Iida1
  • Akira Tachibana1
  • Mitsuru Tomizawa1
  • Kenta Ohnishi1
  • Shunta Hori1
  • Yosuke Morizawa1
3 more authors
  • Daisuke Gotoh1
  • Yasushi Nakai1
  • Nobumichi Tanaka1,2
  1. 1Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Nara, Japan.
  2. 2Department of Prostate Brachytherapy, https://ror.org/045ysha14Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Nara, Japan.
Read full textPDFDOICite

Abstract

This study investigated whether neoadjuvant chemotherapy (NAC) influences the detectability of fibroblast growth factor receptor 3 gene alterations (FGFR3alt) in muscle-invasive bladder cancer (MIBC). Among 173 patients who underwent radical cystectomy (RC), 70 had paired transurethral resection of bladder tumor (TURBT) and RC archival specimens available for FGFR3 RNA testing and immunohistochemical (IHC) analysis. FGFR3alt were detected in only six tumors (8.6%), and 13 RC specimens (19%) showed RNA test failure, predominantly in archival samples older than 10 years. The assay-success concordance of FGFR3 RNA test results between paired TURBT and RC specimens was high (73%), although one NAC-treated patient with FGFR3alt TURBT tissue converted to FGFR3-negative status in the RC specimen. IHC analysis demonstrated significantly higher FGFR3 protein expression in FGFR3alt tumors and a moderate correlation between paired TURBT and RC specimens, irrespective of NAC exposure. Because FGFR3 alterations were detected in only a small number of cases, the study was underpowered to evaluate whether NAC influences FGFR3alt detectability. These findings underscore the need for validation in larger, multi-institutional datasets and integrated molecular profiling to clarify the impact of chemotherapy on FGFR3-driven bladder cancer biology.

Related

  1. Prognostic Impact of Nectin4 and IRF6 Expression in Patients Undergoing Radical Cystectomy for Muscle-Invasive Bladder Cancer.
    Dominik Enderlin, Maria Gloor, Uwe Bieri +6
    Cancer diagnosis & prognosisPeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaEurope PMCPMC
  2. Optimal timing of adjuvant immunotherapy after radical cystectomy in muscle-invasive bladder cancer: from calendar-based to MRD-guided decision making
    Nabih Naim, Ahmad Saad, Nesrine Mohamad +1
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textSurgery & anaesthesiaCrossrefPMC
  3. Predicting acute kidney injury after radical cystectomy for muscle-invasive bladder cancer.
    Kays Chaker, Ahmed Chaabouni, Wafa Elleuch +12
    BMC urologyPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMCDOAJ
  4. Tumor glycosylation and ABO phenotyping alterations in invasive urothelial carcinoma: A case report.
    Vanessa Cristina Fanger, Isabelle Carolina Cotrim Gozzi, Marina Cavalcanti de Albuquerque da Veiga Conrado +4
    Hematology, transfusion and cell therapyPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. ALTERED AND DISTINCT IODOTHYRONINE DEOIDINASE M-RNA EXPRESSION PROFILES IN SURGICAL SPECIMENS OF MULTINODULAR GOITRE AND DIFFERENTIATED THYROID CARCINOMA
    Anjali R. Nair, Abilash Nair, P. K. Jabbar +5
    Thyroid Research & PracticePeer-reviewedCC BY-NC-NDFull textEndocrinology & metabolismDOAJ

Cite

BibTeXRIS
BibTeX
@article{miyake2026fgfr3,
  title = {{FGFR3 Gene Alterations and Protein Expression in Paired TURBT and Radical Cystectomy Archival Specimens of Muscle-Invasive Bladder Cancer.}},
  author = {Makito Miyake and Nobutaka Nishimura and Sayuri Ohnishi and Yuki Oda and Takuto Shimizu and Takuya Owari and Kota Iida and Akira Tachibana and Mitsuru Tomizawa and Kenta Ohnishi and Shunta Hori and Yosuke Morizawa and Daisuke Gotoh and Yasushi Nakai and Nobumichi Tanaka},
  journal = {International journal of molecular sciences},
  year = {2026},
  month = sep,
  doi = {10.3390/ijms27198698},
  url = {https://europepmc.org/article/MED/42883942},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - FGFR3 Gene Alterations and Protein Expression in Paired TURBT and Radical Cystectomy Archival Specimens of Muscle-Invasive Bladder Cancer.
AU  - Makito Miyake
AU  - Nobutaka Nishimura
AU  - Sayuri Ohnishi
AU  - Yuki Oda
AU  - Takuto Shimizu
AU  - Takuya Owari
AU  - Kota Iida
AU  - Akira Tachibana
AU  - Mitsuru Tomizawa
AU  - Kenta Ohnishi
AU  - Shunta Hori
AU  - Yosuke Morizawa
AU  - Daisuke Gotoh
AU  - Yasushi Nakai
AU  - Nobumichi Tanaka
PY  - 2026
DA  - 2026/09/29
JO  - International journal of molecular sciences
DO  - 10.3390/ijms27198698
UR  - https://europepmc.org/article/MED/42883942
AB  - This study investigated whether neoadjuvant chemotherapy (NAC) influences the detectability of fibroblast growth factor receptor 3 gene alterations (FGFR3alt) in muscle-invasive bladder cancer (MIBC). Among 173 patients who underwent radical cystectomy (RC), 70 had paired transurethral resection of bladder tumor (TURBT) and RC archival specimens available for FGFR3 RNA testing and immunohistochemical (IHC) analysis. FGFR3alt were detected in only six tumors (8.6%), and 13 RC specimens (19%) showed RNA test failure, predominantly in archival samples older than 10 years. The assay-success concordance of FGFR3 RNA test results between paired TURBT and RC specimens was high (73%), although one NAC-treated patient with FGFR3alt TURBT tissue converted to FGFR3-negative status in the RC specimen. IHC analysis demonstrated significantly higher FGFR3 protein expression in FGFR3alt tumors and a moderate correlation between paired TURBT and RC specimens, irrespective of NAC exposure. Because FGFR3 alterations were detected in only a small number of cases, the study was underpowered to evaluate whether NAC influences FGFR3alt detectability. These findings underscore the need for validation in larger, multi-institutional datasets and integrated molecular profiling to clarify the impact of chemotherapy on FGFR3-driven bladder cancer biology.
SN  - 1422-0067
ER  -